[go: up one dir, main page]

NO20081526L - Farmasoytisk preparat med fremragende fotostabilitet - Google Patents

Farmasoytisk preparat med fremragende fotostabilitet

Info

Publication number
NO20081526L
NO20081526L NO20081526A NO20081526A NO20081526L NO 20081526 L NO20081526 L NO 20081526L NO 20081526 A NO20081526 A NO 20081526A NO 20081526 A NO20081526 A NO 20081526A NO 20081526 L NO20081526 L NO 20081526L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
pitavastatin
excellent photo
photo stability
stability
Prior art date
Application number
NO20081526A
Other languages
English (en)
Inventor
Masato Kozaki
Yoshio Tanizawa
Hiroyuki Kawashima
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NO20081526L publication Critical patent/NO20081526L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet et farmasøytisk preparat med høy fotostabilitet som inneholder pitavastatin (som er en HMG-CoA reduktase-inhibitor), et salt eller en ester derav. Det farmasøytiske preparatet inneholder en pitavastatin-forbindelse, titanoksid og et fargemiddel som har en maksimum absorpsjonsbølgelengde på 400 nm til 500 nm.
NO20081526A 2005-10-31 2008-03-28 Farmasoytisk preparat med fremragende fotostabilitet NO20081526L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005316758 2005-10-31
PCT/JP2006/321632 WO2007052592A1 (ja) 2005-10-31 2006-10-30 光安定性に優れた医薬製剤

Publications (1)

Publication Number Publication Date
NO20081526L true NO20081526L (no) 2008-07-29

Family

ID=38005744

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081526A NO20081526L (no) 2005-10-31 2008-03-28 Farmasoytisk preparat med fremragende fotostabilitet

Country Status (23)

Country Link
US (1) US20090041843A1 (no)
EP (1) EP1944029B1 (no)
JP (3) JP5166876B2 (no)
KR (1) KR101409087B1 (no)
CN (1) CN101300010B (no)
AT (1) ATE537827T1 (no)
AU (1) AU2006309826B2 (no)
CA (1) CA2626309A1 (no)
CY (1) CY1112477T1 (no)
DK (1) DK1944029T3 (no)
EA (1) EA016713B1 (no)
ES (1) ES2375643T3 (no)
IL (1) IL190346A (no)
NO (1) NO20081526L (no)
NZ (1) NZ566872A (no)
PL (1) PL1944029T3 (no)
PT (1) PT1944029E (no)
SG (1) SG196789A1 (no)
SI (1) SI1944029T1 (no)
TW (1) TWI422375B (no)
UA (1) UA92920C2 (no)
WO (1) WO2007052592A1 (no)
ZA (1) ZA200803655B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
JP5591128B2 (ja) * 2009-01-29 2014-09-17 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
JP2012041290A (ja) * 2010-08-18 2012-03-01 Sawai Pharmaceutical Co Ltd ラフチジン含有固形製剤
JP5809467B2 (ja) * 2011-07-12 2015-11-11 エルメッド エーザイ株式会社 ピタバスタチン含有組成物及びその製造方法
JP5844573B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する錠剤
JP5844574B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する安定化された薬物組成物
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
KR101461841B1 (ko) 2012-08-08 2014-11-13 코와 가부시키가이샤 의약
KR20220164069A (ko) 2013-06-06 2022-12-12 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
JP6150703B2 (ja) * 2013-10-08 2017-06-21 ダイト株式会社 ピタバスタチンカルシウム塩の分解抑制方法
JP6243265B2 (ja) * 2014-03-20 2017-12-06 日医工株式会社 ロスバスタチン含有医薬製剤
JP6433400B2 (ja) * 2014-09-30 2018-12-05 株式会社三和化学研究所 ＨＭＧ−ＣｏＡレダクターゼ阻害薬を含有する医薬製剤
CN104367560A (zh) * 2014-10-23 2015-02-25 万全万特制药江苏有限公司 一种新型匹伐他汀钙口腔崩解片组合物及其制备方法
ES2821733T3 (es) 2015-03-19 2021-04-27 Daiichi Sankyo Co Ltd Preparación sólida que contiene colorante
KR102426821B1 (ko) 2015-03-19 2022-07-28 다이이찌 산쿄 가부시키가이샤 항산화제를 함유하는 고형 제제
JP6072884B2 (ja) * 2015-11-19 2017-02-01 共和薬品工業株式会社 ピタバスタチンを含有する製剤
KR102602820B1 (ko) 2017-01-30 2023-11-15 시오노기세이야쿠가부시키가이샤 퀴나졸린 유도체를 함유하는 고형 제제
TWI795462B (zh) 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
CN108543075A (zh) * 2018-04-29 2018-09-18 广东伊茗药业有限公司 一种光稳定性优异的医药制剂
ES2943883T3 (es) 2018-07-30 2023-06-16 Daiichi Sankyo Co Ltd Formulación de fármaco sólido que contiene estabilizador
EA202191371A1 (ru) * 2018-12-14 2021-12-27 Фуджифилм Корпорэйшн Фармацевтическая композиция и способ ее получения
CN112402388A (zh) * 2019-08-05 2021-02-26 江苏亚虹医药科技股份有限公司 一种用于治疗膀胱癌的口服固体制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU432703A3 (no) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
JPS5522645A (en) * 1978-08-07 1980-02-18 Fujisawa Pharmaceut Co Ltd Soft capsule for encapsulation of light-unstable compound
JPS6059205B2 (ja) * 1981-12-24 1985-12-24 帝三製薬株式会社 光不安定性薬物を包容するための軟カプセルの製造方法
JPS61275214A (ja) * 1985-05-28 1986-12-05 Sawai Seiyaku Kk 経口用メナテトレノン軟カプセル
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
DE4446470A1 (de) * 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
US6465477B1 (en) * 1997-08-18 2002-10-15 Kowa Company, Ltd. Stable pharmaceutical composition
ATE241341T1 (de) * 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
JP2000191516A (ja) * 1998-10-23 2000-07-11 Taisho Pharmaceut Co Ltd 経口固形組成物
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2003104887A (ja) * 2001-09-28 2003-04-09 Maruko Seiyaku Kk 光に安定なアラニジピン含有組成物
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
AU2005245027B2 (en) * 2004-05-21 2011-05-19 Accu-Break Technologies, Inc. Pharmaceutical tablets having a separation mark positioned on the side of said tablets
JP5114382B2 (ja) * 2005-04-08 2013-01-09 アボット・ラボラトリーズ フェノフィブリン酸および／またはそれの塩を含む経口医薬製剤

Also Published As

Publication number Publication date
KR101409087B1 (ko) 2014-06-17
JP2013014610A (ja) 2013-01-24
HK1124772A1 (en) 2009-07-24
CN101300010A (zh) 2008-11-05
IL190346A (en) 2013-06-27
PT1944029E (pt) 2012-02-09
JP5166876B2 (ja) 2013-03-21
KR20080058449A (ko) 2008-06-25
TW200800191A (en) 2008-01-01
NZ566872A (en) 2010-12-24
EA200800993A1 (ru) 2008-08-29
JP5677391B2 (ja) 2015-02-25
EP1944029B1 (en) 2011-12-21
EP1944029A1 (en) 2008-07-16
ATE537827T1 (de) 2012-01-15
SG196789A1 (en) 2014-02-13
PL1944029T3 (pl) 2012-05-31
ES2375643T3 (es) 2012-03-02
TWI422375B (zh) 2014-01-11
EA016713B1 (ru) 2012-07-30
US20090041843A1 (en) 2009-02-12
CN101300010B (zh) 2012-06-06
AU2006309826A1 (en) 2007-05-10
DK1944029T3 (da) 2012-01-23
AU2006309826B2 (en) 2012-01-19
EP1944029A4 (en) 2011-01-12
IL190346A0 (en) 2009-09-22
WO2007052592A1 (ja) 2007-05-10
CY1112477T1 (el) 2015-12-09
SI1944029T1 (sl) 2012-03-30
CA2626309A1 (en) 2007-05-10
UA92920C2 (ru) 2010-12-27
JPWO2007052592A1 (ja) 2009-04-30
ZA200803655B (en) 2009-10-28
JP2012246325A (ja) 2012-12-13

Similar Documents

Publication Publication Date Title
NO20081526L (no) Farmasoytisk preparat med fremragende fotostabilitet
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
NO20090370L (no) Kombinasjon av HMG-Coa-reduktaseinhibitor rosuvastatin med en fosfodiesterase 4-inhibitor, som roflumilast, roflumilast-N-oxid for behandling av inflammatoriske lungesykdommer.
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
AU2003245313A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
EP2300453A4 (en) 3.4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENININHIBITORS
EP2274295A4 (en) 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
BRPI0412636A (pt) imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
IL190024A0 (en) Stabilized protease composition
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
FR2896158B1 (fr) Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
ATE496025T1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
DE602004029362D1 (de) Vermeidung von vorhofflimmern (af) mit der verwendung von statin
EA200501499A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ п-ДИАМИНОБЕНЗОЛА
NO20080722L (no) Anvendelse av 4-(3,4-dijklorfenyl)-1,2,3,4-tetrahydronaftalen-1-ylamin for behandling av kreft
TH93113B (th) ผลิตภัณฑ์ทางเภสัชกรรมที่มีความเสถียรต่อแสงดีเยี่ยม
EA200700322A1 (ru) Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов
WO2006027344A3 (en) 3-oxa-10-aza-phenanthrenes as pde4 or pde3/4 inhibitors
WO2007006922A8 (fr) Nouveaux derives 1h-indole-pyridinecarboxamides et 1h-indole-piperidinecarboxamide et leur utilisation comme inducteurs de tyrosine hydroxylase
DK1601361T3 (da) Pyridylsulfonamidopyrimidiner til behandling af iabetisk nefropati
WO2006097809A3 (en) Novel tyrosine derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application